Research programme: Ebola immunotherapeutics - Regen BioPharma
Latest Information Update: 17 Nov 2014
Price : $50
At a glance
- Originator Regen BioPharma
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Ebola virus infections
Most Recent Events
- 28 Oct 2014 Early research in Ebola virus infections in USA (unspecified route)
- 28 Oct 2014 Regen BioPharma's Ebola immunotherapeutics are available for licensing as of 28 Oct 2014.